arrow_back Trending Legislation
Share share

Prescription Drug Price Relief Act: Ending High-Cost Monopolies

This act aims to lower prescription drug prices in the U.S. It establishes a process to identify drugs with prices higher than in other countries, then allows for the production of cheaper alternatives. This could lead to lower healthcare costs and improved access to essential medications for citizens.
Key points
The government will compare U.S. drug prices with those in Canada, UK, Germany, France, and Japan to identify overpriced drugs.
If a drug is deemed excessively priced, the government can allow other companies to produce cheaper versions, increasing competition.
Drug manufacturers must regularly report pricing and cost data, facing penalties for non-compliance.
A public database will be created, allowing anyone to see which drugs are overpriced and for which cheaper alternatives are available.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Prescription Drug Price Relief Act of 2021
Print number: S 909
Sponsor: Sen. Sanders, Bernard [I-VT]
Process start date: 2021-03-23
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Prescription Drug Price Relief Act: Ending High-Cost Monopolies

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 909.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-03-23.

What are the main provisions?

Key points include:

  • The government will compare U.S. drug prices with those in Canada, UK, Germany, France, and Japan to identify overpriced drugs.
  • If a drug is deemed excessively priced, the government can allow other companies to produce cheaper versions, increasing competition.
  • Drug manufacturers must regularly report pricing and cost data, facing penalties for non-compliance.
  • A public database will be created, allowing anyone to see which drugs are overpriced and for which cheaper alternatives are available.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Sanders, Bernard [I-VT].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

Analysis and Potential Impact of S 909

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Economy